Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""ElNaggar AC"" wg kryterium: Autor


Wyświetlanie 1-17 z 17
Tytuł:
EE430 Utilization of Medical Records Versus Insurance Claims for Outcomes Research: Learnings from Validation of an Ovarian Cancer Lines of Therapy Algorithm
Autorzy:
Simmons, D
Pokaż więcej
Źródło:
In Value in Health July 2022 25(7) Supplement:S419-S419
Czasopismo naukowe
Tytuł:
Clinical outcomes in patients with COVID-19 and gynecologic cancer: A society of gynecologic oncology COVID-19 and gynecologic cancer registry study.
Autorzy:
Glaser GE; Mayo Clinic Division of Gynecologic Surgery, Department of Obstetrics and Gynecology, United States of America. Electronic address: .
Lara OD; Department of Obstetrics and Gynecology, NYU Langone Health, Perlmutter Cancer Center, New York, NY, United States of America.
Pothuri B; Department of Obstetrics and Gynecology, NYU Langone Health, Perlmutter Cancer Center, New York, NY, United States of America.
Grimaldi CG; Vanderbilt, United States of America.
Prescott LS; Vanderbilt, United States of America.
Mastroyannis SA; University of Pennsylvania, United States of America.
Kim S; University of Pennsylvania, United States of America.
ElNaggar AC; West Cancer Center and Research Institute, Memphis, TN, United States of America.
Torres D; Oschner Health, United States of America.
Conrad LB; Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, Creighton University School of Medicine, Omaha, NE, United States of America.
McGree M; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, United States of America.
Weaver A; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, United States of America.
Huh WK; Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, University of Alabama at Birmingham Heersink School of Medicine, United States of America.
Cohn DE; Ohio State University, James Cancer Hospital and Solove Research Institute, United States of America.
Yamada SD; Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Chicago Medicine, United States of America.
Fader AN; Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins School of Medicine, United States of America.
Pokaż więcej
Źródło:
Gynecologic oncology [Gynecol Oncol] 2022 Sep 22. Date of Electronic Publication: 2022 Sep 22.
Typ publikacji:
Journal Article
Czasopismo naukowe
Tytuł:
Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer.
Autorzy:
Hou JY; Columbia University Irving Medical Center, New York City, NY, United States of America. Electronic address: .
Chapman JS; University of California, San Francisco, CA, United States of America.
Kalashnikova E; Natera, Inc., Austin, TX, United States of America.
Pierson W; University of California, San Francisco, CA, United States of America.
Smith-McCune K; University of California, San Francisco, CA, United States of America.
Pineda G; University of California, San Francisco, CA, United States of America.
Vattakalam RM; Columbia University Irving Medical Center, New York City, NY, United States of America.
Ross A; Stanford University, Stanford, CA, United States of America.
Mills M; Stanford University, Stanford, CA, United States of America.
Suarez CJ; Stanford University, Stanford, CA, United States of America.
Davis T; University of Pittsburgh School of Medicine, Pittsburgh, PA, United States of America.
Edwards R; University of Pittsburgh School of Medicine, Pittsburgh, PA, United States of America.
Boisen M; University of Pittsburgh School of Medicine, Pittsburgh, PA, United States of America.
Sawyer S; Natera, Inc., Austin, TX, United States of America.
Wu HT; Natera, Inc., Austin, TX, United States of America.
Dashner S; Natera, Inc., Austin, TX, United States of America.
Aushev VN; Natera, Inc., Austin, TX, United States of America.
George GV; Natera, Inc., Austin, TX, United States of America.
Malhotra M; Natera, Inc., Austin, TX, United States of America.
Zimmermann B; Natera, Inc., Austin, TX, United States of America.
Sethi H; Natera, Inc., Austin, TX, United States of America.
ElNaggar AC; Natera, Inc., Austin, TX, United States of America.
Aleshin A; Natera, Inc., Austin, TX, United States of America.
Ford JM; Stanford University, Stanford, CA, United States of America. Electronic address: .
Pokaż więcej
Źródło:
Gynecologic oncology [Gynecol Oncol] 2022 Sep 15. Date of Electronic Publication: 2022 Sep 15.
Typ publikacji:
Journal Article
Czasopismo naukowe
Tytuł:
Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis.
Autorzy:
Cadoo K; Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College, New York, NY, USA,. Electronic address: .
Simpkins F; Department of Obstetrics and Gynecology, Jordan Center for Gynecologic Oncology at the Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Mathews C; Program in Women's Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Brown University, Providence, RI, USA.
Liu YL; Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College, New York, NY, USA.
Provencher D; CHUM Gynecologie-Oncologie, Montreal, QC, Canada.
McCormick C; Legacy Medical Group Gynecologic Oncology, Portland, OR, USA.
ElNaggar AC; West Cancer Center and Research Institute, Memphis, TN, USA.
Altman AD; CancerCare Manitoba, Research Institute of Oncology and Hematology, University of Manitoba, Winnipeg, Manitoba, Canada.
Gilbert L; Division of Gynecologic Oncology, McGill University Health Centre, Montreal, Quebec, Canada.
Black D; Willis-Knighton Cancer Center, Shreveport, LA, USA.
Kabil N; AstraZeneca, Gaithersburg, MD, USA.
Bennett J; AstraZeneca, Cambridge, UK.
Munley J; AstraZeneca, Wilmington, DE, USA.
Aghajanian C; Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College, New York, NY, USA.
Pokaż więcej
Źródło:
Gynecologic oncology [Gynecol Oncol] 2022 Sep; Vol. 166 (3), pp. 425-431. Date of Electronic Publication: 2022 Jul 05.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Ovarian Neoplasms*/drug therapy
Ovarian Neoplasms*/genetics
Ovarian Neoplasms*/pathology
BRCA1 Protein/genetics ; BRCA2 Protein/genetics ; Carcinoma, Ovarian Epithelial/drug therapy ; Carcinoma, Ovarian Epithelial/genetics ; Female ; Homologous Recombination ; Humans ; Mutation ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/genetics ; Phthalazines ; Piperazines
Czasopismo naukowe
Tytuł:
Molecular profiles of endometrial cancer tumors among Black patients.
Autorzy:
Wilhite AM; Mitchell Cancer Institute, University of South Alabama, Division of Gynecologic Oncology Mobile, AL, United States of America. Electronic address: .
Baca Y; Caris Life Sciences, Pheonix, AZ, United States of America.
Xiu J; Caris Life Sciences, Pheonix, AZ, United States of America.
Paladugu R; Mitchell Cancer Institute, University of South Alabama, Division of Gynecologic Oncology Mobile, AL, United States of America.
ElNaggar AC; West Cancer Center and Research Institute, Division of Gynecologic Oncology, Memphis, TN, United States of America.
Brown J; Atrium Health, Division of Gynecologic Oncology, Charlotte, NC, United States of America.
Winer IS; Wayne State University and Karmanos Cancer Institute, Division of Gynecologic Oncology, Detroit, MI, United States of America.
Morris R; Wayne State University and Karmanos Cancer Institute, Division of Gynecologic Oncology, Detroit, MI, United States of America.
Erickson BK; University of Minnesota, Division of Gynecologic Oncology, Minneapolis, MN, United States of America.
Olawaiye AB; Magee-Womens Hospital, University of Pittsburgh Medical Center, Division of Gynecologic Oncology, Pittsburgh, PA, United States of America.
Powell M; University of Alabama at Birmingham, Division of Gynecologic Oncology, Birmingham, AL, United States of America.
Korn WM; Caris Life Sciences, Pheonix, AZ, United States of America.
Rocconi RP; University of Alabama at Birmingham, Division of Gynecologic Oncology, Birmingham, AL, United States of America.
Khabele D; Washington University, Division of Gynecologic Oncology, St. Louis, MO, United States of America.
Jones NL; Mitchell Cancer Institute, University of South Alabama, Division of Gynecologic Oncology Mobile, AL, United States of America.
Pokaż więcej
Źródło:
Gynecologic oncology [Gynecol Oncol] 2022 Jul; Vol. 166 (1), pp. 108-116. Date of Electronic Publication: 2022 Apr 28.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Endometrioid*/genetics
Carcinoma, Endometrioid*/pathology
Carcinosarcoma*/genetics
Carcinosarcoma*/pathology
Endometrial Neoplasms*/pathology
Blacks ; Female ; Humans ; Microsatellite Instability ; Mutation
Czasopismo naukowe
Tytuł:
Health Care Resource Utilization and Costs Associated with Disease Progression in Ovarian Cancer.
Autorzy:
Simmons D; US Oncology Health Economics and Outcomes Research, AstraZeneca, 1 Medimmune Way, Gaithersburg, MD, 20878, USA. .
Blank SV; Icahn School of Medicine at Mount Sinai, Blavatnik Family Women's Health Research Institute, New York, NY, USA.
ElNaggar AC; WEST Cancer Center and Research Institute, Memphis, TN, USA.
Chastek B; Optum, Eden Prairie, MN, USA.
Bunner SH; Optum, Eden Prairie, MN, USA.
McLaurin K; US Oncology Health Economics and Outcomes Research, AstraZeneca, 1 Medimmune Way, Gaithersburg, MD, 20878, USA.
Pokaż więcej
Źródło:
Advances in therapy [Adv Ther] 2022 Jun; Vol. 39 (6), pp. 2544-2561. Date of Electronic Publication: 2022 Apr 01.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Medicare*
Ovarian Neoplasms*/drug therapy
Aged ; Carcinoma, Ovarian Epithelial/therapy ; Delivery of Health Care ; Disease Progression ; Female ; Health Care Costs ; Humans ; Retrospective Studies ; United States
Czasopismo naukowe
Tytuł:
Same-day discharge after robotic surgery for endometrial cancer.
Autorzy:
Zhang N; Department of Obstetrics and Gynecology, The University of Tennessee Health Science Center, Memphis, TN, USA.
Wilson B; Division of Gynecologic Oncology, West Cancer Center and Research Institute, 7945 Wolf River Blvd., Memphis, TN, 38138, USA.
Enty MA; Department of Obstetrics and Gynecology, The University of Tennessee Health Science Center, Memphis, TN, USA.
Ketch P; Department of Obstetrics and Gynecology, The University of Tennessee Health Science Center, Memphis, TN, USA.
Ulm MA; Division of Gynecologic Oncology, West Cancer Center and Research Institute, 7945 Wolf River Blvd., Memphis, TN, 38138, USA.
ElNaggar AC; Division of Gynecologic Oncology, West Cancer Center and Research Institute, 7945 Wolf River Blvd., Memphis, TN, 38138, USA.
Daily L; Division of Gynecologic Oncology, West Cancer Center and Research Institute, 7945 Wolf River Blvd., Memphis, TN, 38138, USA.
Tillmanns T; Division of Gynecologic Oncology, West Cancer Center and Research Institute, 7945 Wolf River Blvd., Memphis, TN, 38138, USA. .
Pokaż więcej
Źródło:
Journal of robotic surgery [J Robot Surg] 2022 Jun; Vol. 16 (3), pp. 543-548. Date of Electronic Publication: 2021 Jul 08.
Typ publikacji:
Journal Article
Czasopismo naukowe
Tytuł:
Integrin-Linked Kinase Is a Novel Therapeutic Target in Ovarian Cancer.
Autorzy:
Ulm MA; Division of Gynecologic Oncology, West Cancer Center and Research Institute, Memphis, TN 38138, USA.
Redfern TM; Division of Gynecologic Oncology, West Cancer Center and Research Institute, Memphis, TN 38138, USA.
Wilson BR; Division of Gynecologic Oncology, West Cancer Center and Research Institute, Memphis, TN 38138, USA.
Ponnusamy S; Department of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Asemota S; Department of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Blackburn PW; Division of Gynecologic Oncology, West Cancer Center and Research Institute, Memphis, TN 38138, USA.
Wang Y; Department of Pathology, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
ElNaggar AC; Division of Gynecologic Oncology, West Cancer Center and Research Institute, Memphis, TN 38138, USA.
Narayanan R; Department of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Pokaż więcej
Źródło:
Journal of personalized medicine [J Pers Med] 2020 Nov 26; Vol. 10 (4). Date of Electronic Publication: 2020 Nov 26.
Typ publikacji:
Journal Article
Czasopismo naukowe
Tytuł:
Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial.
Autorzy:
Oaknin A; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Friedman CF; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Roman LD; USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
D'Souza A; USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
Brana I; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Bidard FC; Institut Curie, St Cloud, France.
Goldman J; The David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Alvarez EA; University of California, San Francisco, CA, USA.
Boni V; START Madrid Centro Oncologico Clara Campal (CIOCC), Madrid, Spain.
ElNaggar AC; West Cancer Center and Research Institute, Memphis, TN, USA.
Passalacqua R; Oncologia Medica-ASST Istituti Ospitalieri Cremona, Cremona, Italy.
Do KTM; Dana-Farber Cancer Institute, Boston, MA, USA.
Santin AD; Yale School of Medicine, New Haven, CT, USA.
Keyvanjah K; Puma Biotechnology Inc, Los Angeles, CA, USA.
Xu F; Puma Biotechnology Inc, Los Angeles, CA, USA.
Eli LD; Puma Biotechnology Inc, Los Angeles, CA, USA.
Lalani AS; Puma Biotechnology Inc, Los Angeles, CA, USA.
Bryce RP; Puma Biotechnology Inc, Los Angeles, CA, USA.
Hyman DM; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Meric-Bernstam F; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Solit DB; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Monk BJ; Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, AZ, USA. Electronic address: .
Pokaż więcej
Źródło:
Gynecologic oncology [Gynecol Oncol] 2020 Oct; Vol. 159 (1), pp. 150-156. Date of Electronic Publication: 2020 Jul 25.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Neoplasm Recurrence, Local/*drug therapy
Protein Kinase Inhibitors/*administration & dosage
Quinolines/*administration & dosage
Receptor, ErbB-2/*antagonists & inhibitors
Uterine Cervical Neoplasms/*drug therapy
Administration, Oral ; Adult ; Diarrhea/chemically induced ; Diarrhea/diagnosis ; Diarrhea/epidemiology ; Female ; Humans ; Kaplan-Meier Estimate ; Middle Aged ; Mutation ; Nausea/chemically induced ; Nausea/diagnosis ; Nausea/epidemiology ; Neoplasm Recurrence, Local/genetics ; Neoplasm Recurrence, Local/mortality ; Progression-Free Survival ; Protein Kinase Inhibitors/adverse effects ; Quinolines/adverse effects ; Receptor, ErbB-2/genetics ; Response Evaluation Criteria in Solid Tumors ; Severity of Illness Index ; Uterine Cervical Neoplasms/genetics ; Uterine Cervical Neoplasms/mortality
Czasopismo naukowe
Tytuł:
Time to chemotherapy in ovarian cancer: Compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center.
Autorzy:
ElNaggar AC; Division of Gynecologic Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, United States of America. Electronic address: .
Hade EM; Department of Biomedical Informatics, Center for Biostatistics at The Ohio State University, Columbus, OH, United States of America.
O'Malley DM; Division of Gynecologic Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, United States of America.
Liang MI; Division of Gynecologic Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, United States of America.
Copeland LJ; Division of Gynecologic Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, United States of America.
Fowler JM; Division of Gynecologic Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, United States of America.
Salani R; Division of Gynecologic Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, United States of America.
Backes FJ; Division of Gynecologic Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, United States of America.
Cohn DE; Division of Gynecologic Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, United States of America.
Pokaż więcej
Źródło:
Gynecologic oncology [Gynecol Oncol] 2018 Dec; Vol. 151 (3), pp. 501-505. Date of Electronic Publication: 2018 Sep 30.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Chemotherapy, Adjuvant/*methods
Ovarian Neoplasms/*drug therapy
Female ; Humans ; Middle Aged ; National Cancer Institute (U.S.) ; United States
Czasopismo naukowe
Tytuł:
Celecoxib versus ketorolac following robotic hysterectomy for the management of postoperative pain: An open-label randomized control trial.
Autorzy:
Ulm MA; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Tennessee Health Science Center, West Cancer Center, 7945 Wolf River Boulevard, Germantown, TN 38138, United States of America. Electronic address: .
ElNaggar AC; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Tennessee Health Science Center, West Cancer Center, 7945 Wolf River Boulevard, Germantown, TN 38138, United States of America. Electronic address: .
Tillmanns TD; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Tennessee Health Science Center, West Cancer Center, 7945 Wolf River Boulevard, Germantown, TN 38138, United States of America. Electronic address: .
Pokaż więcej
Źródło:
Gynecologic oncology [Gynecol Oncol] 2018 Oct; Vol. 151 (1), pp. 124-128. Date of Electronic Publication: 2018 Aug 16.
Typ publikacji:
Comparative Study; Journal Article; Randomized Controlled Trial
MeSH Terms:
Celecoxib/*therapeutic use
Cyclooxygenase Inhibitors/*therapeutic use
Endometrial Neoplasms/*surgery
Ketorolac/*therapeutic use
Pain Management/*methods
Pain, Postoperative/*drug therapy
Activities of Daily Living ; Administration, Intravenous ; Administration, Oral ; Adult ; Aged ; Analgesics, Opioid/therapeutic use ; Drug Therapy, Combination/methods ; Female ; Humans ; Hysterectomy/adverse effects ; Hysterectomy/methods ; Middle Aged ; Pain Measurement/drug effects ; Pain, Postoperative/epidemiology ; Pain, Postoperative/etiology ; Robotic Surgical Procedures/adverse effects ; Robotic Surgical Procedures/methods ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Recurrent low grade serous ovarian cancer in a 20 year old woman: A case from the Ohio State University College of Medicine.
Autorzy:
Cohn DE; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Ohio State University College of Medicine, Columbus, OH, United States. Electronic address: .
Backes FJ; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Ohio State University College of Medicine, Columbus, OH, United States.
Wallbillich JJ; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Ohio State University College of Medicine, Columbus, OH, United States.
Bixel K; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Ohio State University College of Medicine, Columbus, OH, United States.
Crafton SM; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Ohio State University College of Medicine, Columbus, OH, United States.
Neff R; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Ohio State University College of Medicine, Columbus, OH, United States.
ElNaggar AC; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Ohio State University College of Medicine, Columbus, OH, United States.
Smith B; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Ohio State University College of Medicine, Columbus, OH, United States.
Suarez AA; Department of Pathology, Ohio State University College of Medicine, Columbus, OH, United States.
Pokaż więcej
Źródło:
Gynecologic oncology [Gynecol Oncol] 2017 Mar; Vol. 144 (3), pp. 451-455. Date of Electronic Publication: 2017 Feb 01.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Neoplasm Recurrence, Local/*pathology
Ovarian Neoplasms/*pathology
Adult ; Female ; Humans ; Neoplasm Grading ; Ohio ; Ovarian Neoplasms/therapy ; Young Adult
Czasopismo naukowe
Tytuł:
Addition of Everolimus Post VEGFR Inhibition Treatment Failure in Advanced Sarcoma Patients Who Previously Benefited from VEGFR Inhibition: A Case Series.
Autorzy:
ElNaggar AC; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University, Columbus, Ohio, United States of America.
Hays JL; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University, Columbus, Ohio, United States of America.; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, United States of America.
Chen JL; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, United States of America.; Division of Bioinformatics, Department of Biomedical Informatics, The Ohio State University, Columbus, Ohio, United States of America.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2016 Jun 13; Vol. 11 (6), pp. e0156985. Date of Electronic Publication: 2016 Jun 13 (Print Publication: 2016).
Typ publikacji:
Journal Article; Observational Study
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Bone Neoplasms/*drug therapy
Everolimus/*administration & dosage
Protein Kinase Inhibitors/*administration & dosage
Receptors, Vascular Endothelial Growth Factor/*antagonists & inhibitors
Sarcoma/*drug therapy
Soft Tissue Neoplasms/*drug therapy
Adult ; Bone Neoplasms/pathology ; Chemotherapy, Adjuvant ; Disease Progression ; Everolimus/adverse effects ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Metastasis ; Protein Kinase Inhibitors/adverse effects ; Retrospective Studies ; Sarcoma/pathology ; Soft Tissue Neoplasms/pathology ; Treatment Failure
Czasopismo naukowe
Tytuł:
Incidence and contributing factors to termination of the patient-physician relationship.
Autorzy:
Santoso JT; Division of Gynecology Oncology, University of Tennessee-West Cancer Center, Memphis, TN, United States.
Yibirin E; University of Tennessee Health Science Center, Memphis, TN, United States.
Crigger M; Division of Gynecology Oncology, University of Tennessee-West Cancer Center, Memphis, TN, United States.
Wan J; Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, TN, United States.
ElNaggar AC; Division of Gynecologic Oncology, The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solve Research Institute, Columbus, OH, United States.
Pokaż więcej
Źródło:
Gynecologic oncology reports [Gynecol Oncol Rep] 2016 May 31; Vol. 17, pp. 42-4. Date of Electronic Publication: 2016 May 31 (Print Publication: 2016).
Typ publikacji:
Case Reports
Raport
Tytuł:
Setting the bar: compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center.
Autorzy:
Liang MI; Division of Gynecologic Oncology Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, Columbus, OH, USA.
ElNaggar AC; Division of Gynecologic Oncology Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, Columbus, OH, USA.
Nekkanti S; Division of Gynecologic Oncology Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, Columbus, OH, USA.
O'Malley DM; Division of Gynecologic Oncology Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, Columbus, OH, USA.
Hade EM; Center for Biostatistics, Department of Biomedical Informatics, The Ohio State University College of Medicine, Columbus, OH, USA.
Copeland LJ; Division of Gynecologic Oncology Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, Columbus, OH, USA.
Fowler JM; Division of Gynecologic Oncology Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, Columbus, OH, USA.
Salani R; Division of Gynecologic Oncology Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, Columbus, OH, USA.
Backes FJ; Division of Gynecologic Oncology Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, Columbus, OH, USA.
Cohn DE; Division of Gynecologic Oncology Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, Columbus, OH, USA. Electronic address: .
Pokaż więcej
Źródło:
Gynecologic oncology [Gynecol Oncol] 2015 Sep; Vol. 138 (3), pp. 689-93. Date of Electronic Publication: 2015 Jul 26.
Typ publikacji:
Journal Article
MeSH Terms:
Medical Oncology/*methods
Medical Oncology/*standards
Ovarian Neoplasms/*drug therapy
Ovarian Neoplasms/*surgery
Adult ; Aged ; Aged, 80 and over ; Female ; Guideline Adherence ; Humans ; Middle Aged ; National Cancer Institute (U.S.) ; Patient Compliance ; Quality of Health Care ; United States
Czasopismo naukowe
Tytuł:
Guided outcomes in learned efficiency model in clinical medical education: a randomized controlled trial of self-regulated learning.
Autorzy:
Patil AS; Departments of Obstetrics and Gynecology and Medicine, Indiana University School of Medicine, Indianapolis, IN.
Elnaggar AC; Department of Gynecology and Obstetrics, the Ohio State University College of Medicine, Columbus, OH.
Kumar S; Department of Obstetrics and Gynecology, University of Tennessee Health Science Center, Memphis, TN.
Ling FW; Women's Health Specialists, Germantown, TN.
Stritter FT; University of North Carolina School of Medicine, Chapel Hill, NC.
Temiyakarn L; Department of Radiology, University of Tennessee Health Science Center, Memphis, TN.
Tillmanns TD; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Tennessee Health Science Center-West Clinic, Memphis, TN.
Pokaż więcej
Źródło:
American journal of obstetrics and gynecology [Am J Obstet Gynecol] 2014 Nov; Vol. 211 (5), pp. 544.e1-7. Date of Electronic Publication: 2014 Jun 04.
Typ publikacji:
Journal Article; Randomized Controlled Trial
MeSH Terms:
Clinical Competence*
Education, Medical, Undergraduate/*methods
Evidence-Based Medicine/*education
Adult ; Female ; Humans ; Male
Czasopismo naukowe
Tytuł:
Keratosis reduces sensitivity of anal cytology in detecting anal intraepithelial neoplasia.
Autorzy:
ElNaggar AC; Department of Obstetrics & Gynecology, University of Tennessee Health Science Center, Memphis, TN 38163, USA. />Santoso JT
Xie HB
Pokaż więcej
Źródło:
Gynecologic oncology [Gynecol Oncol] 2012 Feb; Vol. 124 (2), pp. 292-5. Date of Electronic Publication: 2011 Oct 20.
Typ publikacji:
Journal Article
MeSH Terms:
Anus Neoplasms/*pathology
Carcinoma in Situ/*pathology
Keratosis/*pathology
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Biopsy ; Female ; Genital Neoplasms, Female/pathology ; Humans ; Middle Aged ; Sensitivity and Specificity ; Young Adult
Czasopismo naukowe
    Wyświetlanie 1-17 z 17

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies

    Prześlij opinię

    Twoje opinie są dla nas bardzo ważne i mogą być niezwykle pomocne w pokazaniu nam, gdzie możemy dokonać ulepszeń. Bylibyśmy bardzo wdzięczni za poświęcenie kilku chwil na wypełnienie krótkiego formularza.

    Formularz